Brief: Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
23/06/2025 13:10
June 23 (Reuters) - Anixa Biosciences Inc ANIX.O: ANIXA BIOSCIENCES INITIATES DOSING IN FOURTH COHORT IN ITS OVARIAN CANCER CAR-T CLINICAL TRIAL ANIXA BIOSCIENCES INC - NO DOSE-LIMITING TOXICITIES OBSERVED IN THIRD COHORT ANIXA BIOSCIENCES INC - FOURTH COHORT DOSE REPRESENTS THIRTYFOLD INCREASE FROM FIRST COHORT Source text: ID:nPn1XJspXa Further company coverage: ANIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine